俄亥俄州从克利夫兰诊所Peter Kaiser博士最新的研究成果指出：新生血管年龄相关性黄斑变性(AMD)的患者，通过玻璃体内注射阿柏西普，可持续改善视力96周。在2项3期临床试验VIEW 1、VIEW2中，在按季度调整用药剂量后，第52周观察到的视力和病理改善结果，至第96周时仍大部分保留。每2个月给予2.0mg阿柏西普与每月给予雷珠单抗的疗效相似。

　　PA057

　　Integrated 96-Week Results From the VIEW 1 & VIEW 2 Studies: Intravitreal Aflibercept Injection in Neovascular AMD

　　Purpose: To assess efficacy and safety of intravitreal aflibercept (IAI) vs. ranibizumab (RBZ).

　　Methods: Patients were randomized to RBZ 0.5 mg monthly (Rq4); IAI 2 mg monthly (2q4), 0.5 mg monthly (0.5q4), or 2 mg every 2 months (2q8) after 3 loading doses. Weeks 52 to 96 patients were treated with modified quarterly dosing.

　　Results: At Week 96, visual acuity (VA) gains were 7.9, 7.6, 6.6, and 7.6 letters, respectively. Most frequent ocular adverse events were conjunctival hemorrhage, eye pain, retinal hemorrhage, and VA reduced.

　　Conclusion:VA improvements with IAI and RBZ at Week 52 were largely maintained through Week 96; efficacy of 2q8 IAI was similar to Rq4.